Core Viewpoint - CICC maintains "outperform" rating for CSPC Pharmaceutical Group (01093) and raises target price by 9.1% to HKD 12, while keeping profit forecasts for 2025 and 2026 at CNY 4.76 billion and CNY 5.35 billion, respectively, and introducing a forecast of CNY 5.70 billion for 2027 [1] Group 1 - CSPC Pharmaceutical has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of eight innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [2] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative milestone payments for development and sales, with Giant Biologics (a subsidiary of New Horizon (300765)) entitled to 35% of the upfront payment and subsequent milestone payments [2] Group 2 - The company is betting on long-acting peptide drugs to compete in the weight loss and metabolic market, with its drug SYH2082 progressing to Phase I clinical trials as a monthly injection GLP1R/GIP agonist [3] - Pfizer's acquisition of Metsera for USD 10 billion highlights the competitive landscape, as Metsera's proprietary NuSH platform enables a long half-life for its weight loss drug MET-097 [3] Group 3 - CSPC has achieved significant external licensing agreements in 2025, including USD 120 million for oral small molecule GLP-1, USD 110 million for the AstraZeneca strategic partnership, and USD 15 million for ROR1ADC, indicating a trend towards regular income from external licensing [4] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC and SiRNA series, which are expected to lead to further successful licensing and milestone revenue recognition [4]

Core Viewpoint - CICC maintains a "outperform" rating for CSPC Pharmaceutical Group (01093) and raises the target price by 9.1% to HKD 12, considering the continued success of external licensing agreements [1] Group 1: Licensing Agreements and Financial Projections - CSPC has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of 8 innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [1] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative development and sales milestone payments [1] - The company maintains its profit forecasts for 2025 and 2026 at RMB 4.76 billion and RMB 5.35 billion, respectively, and introduces a forecast of RMB 5.70 billion for 2027 [1] Group 2: Market Position and Competitive Landscape - The company is positioned in the long-acting peptide drug market, competing with major players like Pfizer, which acquired Metsera for USD 10 billion to enhance its weight loss drug portfolio [2] - CSPC's SYH2082 is advancing to Phase I clinical trials as a long-acting GLP1R/GIP agonist, with expectations for favorable efficacy and safety data [2] Group 3: Revenue Generation from Licensing - In 2025, the company has already achieved external licensing revenues from various projects, including USD 120 million from oral small molecule GLP-1 and USD 110 million from the AstraZeneca strategic collaboration [3] - The company has a pipeline of innovative assets, including EGFR ADC and SiRNA series, which are expected to lead to further successful licensing agreements and milestone revenue recognition [3]

Group 1 - The article highlights the top short-selling ratios for various companies, with JD Health-R, Anta Sports-R, and Lenovo Group-R leading the list at 100.00%, 89.98%, and 89.87% respectively [1][2] - The top three companies by short-selling amount are CSPC Pharmaceutical Group at 1.268 billion, Zijin Mining Group at 1.031 billion, and Xiaomi Group-W at 1.014 billion [1][2] - The highest deviation values in short-selling are recorded for Kuaishou-WR at 36.02%, Xiaomi Group-WR at 30.00%, and Heptagon Pharmaceuticals-B at 26.77% [1][2] Group 2 - The top ten short-selling ratios include JD Health-R at 100.00%, Anta Sports-R at 89.98%, and Lenovo Group-R at 89.87%, with Kuaishou-WR and Xiaomi Group-WR also featuring prominently [2] - The top ten short-selling amounts show CSPC Pharmaceutical Group leading with 1.268 billion, followed by Zijin Mining Group and Xiaomi Group-W [2] - The top ten deviation values indicate significant short-selling activity, particularly for Kuaishou-WR and Xiaomi Group-WR, suggesting potential volatility [2]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of February 1, 2026 [1] Core Insights - The competitiveness of China's active pharmaceutical ingredient (API) exports is supported by technological advancements, with a focus on supply variables [2] - Significant transactions in the industry highlight the ongoing validation of clinical data for innovative drugs, with multiple major deals occurring in early 2026 [3] - Leading companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [4] - A new pricing system for GLP-1 drugs is forming domestically, while the oral GLP-1 market is rapidly expanding in the U.S. [5] - The market value of oral autoimmune drugs is gaining attention, with promising results from key clinical trials [6] Summary by Sections Industry Overview - In 2025, China's pharmaceutical and healthcare product exports reached $111.34 billion, growing by 3.14%, with API exports accounting for $42.87 billion, representing 76.8% of total Western medicine exports [2] - The report notes a 10.6% decline in pharmaceutical exports to the U.S. due to tariff impacts, while the EU and emerging markets saw increases of 11.38% and 4.49%, respectively [2] Major Transactions and Innovations - In January 2026, a significant licensing agreement between CSPC Pharmaceutical and AstraZeneca was announced, involving a $1.2 billion upfront payment and potential milestone payments totaling up to $3.5 billion [3] - The report emphasizes the need for continuous clinical data validation for authorized products to secure future milestone payments [3] Small Nucleic Acid Developments - Leading companies like China Biologic Products are acquiring innovative firms in the small interfering RNA (siRNA) sector, indicating a strategic focus on this area [4] - The report highlights successful clinical trial results for small nucleic acid drugs, which are attracting more attention from major pharmaceutical companies [4] GLP-1 Market Dynamics - A new pricing structure for GLP-1 products is emerging in China, with the anticipated launch of generic versions expected to further influence market prices [5] - The report notes that oral GLP-1 drugs are gaining traction in the U.S., with significant prescription numbers reported shortly after launch [5] Oral Autoimmune Drug Developments - Takeda's new oral TYK2 inhibitor has shown positive results in key clinical trials for psoriasis, indicating a potential breakthrough in oral autoimmune treatments [6] - The report mentions ongoing developments in oral autoimmune drugs targeting various pathways, with several domestic companies advancing their clinical trials [6] Stock Recommendations - The report suggests focusing on companies that are likely to benefit from the API cycle reversal, such as Chuan Ning Biological and Guobang Pharmaceutical, and highlights the potential of small nucleic acid drugs and oral autoimmune treatments [8]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [31] Core Insights - On January 30, 2023, the report highlights that the company has signed a strategic R&D cooperation and licensing agreement with AstraZeneca to develop innovative long-acting peptide drugs using its proprietary sustained-release drug delivery technology and peptide drug AI discovery platform [3] - AstraZeneca will gain global exclusive rights to the company's weight management product portfolio, which includes a clinical-ready project SYH2082 and three preclinical projects targeting obesity and weight-related issues [3] - The company is set to receive $1.2 billion in upfront payments, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion in sales milestone payments, along with a double-digit percentage royalty on annual net sales of the licensed products [3] Summary by Sections Industry Overview - The report emphasizes the increasing recognition of Chinese innovative pharmaceutical companies by international multinational corporations (MNCs), particularly through the recent collaboration with AstraZeneca [4] - The report also notes AstraZeneca's plan to invest $15 billion in China by 2030 to expand drug manufacturing and R&D, leveraging China's scientific capabilities and manufacturing strengths [4] Investment Strategy - The report suggests that the global competitiveness of Chinese innovative pharmaceutical companies is continuously improving, with a focus on potential treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders [5] - It recommends paying attention to emerging fields like small nucleic acid drugs, radioactive drugs, and CAR-T therapies, highlighting specific companies to watch [5] Market Performance - The pharmaceutical sector experienced a decline of 3.31% last week, ranking 20th among 28 industries, while the Hong Kong pharmaceutical sector fell by 2.98% [9][30] - The report indicates that the valuation of the pharmaceutical sector is at 32.45 times (TTM), with a premium of 15.83% compared to the overall A-shares [23]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].

Company Updates - The company announced a research and development collaboration and licensing agreement with AstraZeneca for eight innovative long-acting peptide drug projects, including SYH2082 and three preclinical molecules, with an additional four projects under collaboration [1] - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in development and sales milestone payments, with a subsidiary entitled to receive 35% of the upfront payment and subsequent milestone payments and royalties [1] Industry Insights - The collaboration marks a significant milestone for Chinese innovative drug licensing abroad, as multinational corporations (MNCs) are betting on long-acting peptide drugs to compete in the weight loss and metabolic market [1] - The company’s SYH2082 is a long-acting GLP1R/GIP agonist progressing to Phase I clinical trials, with expectations for more favorable efficacy and safety data [1] Revenue Generation - The company has achieved external licensing agreements in 2025, including $120 million for oral small molecule GLP-1, $110 million for the AstraZeneca collaboration, and $15 million for other projects, indicating a potential for regular income from licensing [2] - The company has a pipeline of innovative assets, including EGFR ADC/SiRNA series, which are expected to lead to further licensing agreements and milestone revenue recognition [2] Profit Forecast and Valuation - The profit forecast for 2025 and 2026 is maintained at 4.76 billion yuan and 5.35 billion yuan, with an introduction of a 2027 forecast of 5.70 billion yuan [2] - The current stock price corresponds to a price-to-earnings ratio of 18.7 and 17.1 times for 2026 and 2027, respectively, with a target price adjustment of 9.1% to HKD 12.00, implying a 25% upside potential [2]

Core Viewpoint - The article highlights the significant transactions in the Chinese innovative drug market, particularly focusing on weight loss and metabolic diseases, with a total potential value of approximately $25.8 billion from collaborations between Shijiazhuang Pharmaceutical Group and AstraZeneca, marking a pivotal moment for Chinese pharmaceutical companies in the global weight loss drug competition [5][8]. Group 1: Transaction Details - The collaboration includes a notable $18.5 billion deal for a long-acting weight management product, which sets a record for external licensing of innovative drugs from China [5]. - Shijiazhuang Pharmaceutical will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and $13.8 billion for sales, along with revenue-sharing agreements [6]. - The partnership extends beyond specific molecules to include Shijiazhuang's sustained-release delivery technology platform and AI drug discovery platform, indicating a long-term strategic collaboration rather than a one-time transaction [6]. Group 2: Market Trends and Competitive Landscape - The focus on long-acting formulations in weight loss drugs is driven by market realities, as competition in weight loss efficacy approaches a ceiling, making dosing frequency and patient adherence critical for commercial success [7]. - Shijiazhuang's sustained-release technology aligns with the industry's shift towards longer dosing intervals, with monthly or longer intervals seen as essential for next-generation weight loss drugs [7]. - The integration of AI-driven drug discovery platforms has proven to be a valuable asset, as demonstrated by previous collaborations with AstraZeneca, which have resulted in high-value agreements for various projects [8]. Group 3: Implications for the Industry - The $25.8 billion in transactions reflects a profound shift in the competitive logic of the global weight loss drug market, moving from simple weight loss metrics to a comprehensive competition involving dosing methods, treatment cycle management, and platform innovation capabilities [8][9]. - Shijiazhuang's multi-layered approach in the weight loss and metabolic field, including long-acting GLP-1 and dual-target projects, oral small molecules, and AI-driven innovations, enhances its bargaining power in collaborations [8]. - As long-acting products enter clinical validation, the competitive threshold in the weight loss drug market will rise, making it strategically important for global pharmaceutical companies to secure partnerships with capable platform providers [9].

Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at up to $18.5 billion, was met with unexpected market skepticism, leading to a significant drop in stock prices for both companies involved [2][4][7]. Group 1: Strategic Collaboration Details - CSPC Pharmaceutical Group announced a strategic partnership with AstraZeneca to co-develop innovative long-acting peptide drugs based on CSPC's drug delivery technology and AI discovery platform [3][4]. - The agreement includes a $1.2 billion upfront payment, up to $3.5 billion in research milestone payments, and $13.8 billion in sales milestone payments, along with a double-digit revenue share based on annual net sales [4][5]. - This deal surpasses the previous record of $11.4 billion set by Innovent Biologics and Takeda in 2025, marking a new high for outbound licensing in China's biopharmaceutical sector [4]. Group 2: Market Reaction and Concerns - Following the announcement, CSPC's stock fell by 9.82% to HKD 9.64 per share, while its closely related company, New Horizon Health, saw a drop of 15.72% [2][7]. - Analysts suggest that the market's negative reaction stems from concerns over the details of the deal and the companies' fundamentals, indicating that the perceived benefits may not align with the actual risks involved [7]. - The milestone payments are contingent on successful clinical trials and market performance, raising questions about the viability of CSPC's projects in a competitive landscape [7][8]. Group 3: Product and Competitive Landscape - The core asset in this collaboration is SYH2082, a long-acting weight management drug currently in Phase I clinical trials, targeting GLP-1R and GIPR receptors [8][9]. - The competitive landscape for GLP-1 drugs is intensifying, with major players like Eli Lilly and domestic companies rapidly advancing their own dual-target and multi-target drugs [9][10]. - CSPC's late entry into the clinical phase with SYH2082 presents challenges in efficacy differentiation and safety optimization, which will be critical for its future competitiveness [10]. Group 4: Financial Context and Implications - CSPC's decision to pursue this significant licensing deal comes at a time when its financial performance is under pressure, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [11]. - New Horizon Health stands to benefit from the upfront payment, which will help alleviate its cash flow issues as it anticipates a significant net loss in 2025 due to high R&D expenditures [12].

Core Viewpoint - The strategic collaboration between Sinopharm (300765) and AstraZeneca marks a significant milestone in the innovation and internationalization strategy of the Chinese pharmaceutical industry, highlighting the global competitiveness of its AI drug discovery and sustained delivery technology platforms [2][4]. Group 1: Collaboration Details - Sinopharm and its indirect controlling shareholder, Shiyao Group, announced a strategic research and licensing agreement with AstraZeneca to develop innovative peptide molecules and long-acting delivery products [1]. - The total potential amount of the collaboration could reach up to $18.5 billion, with AstraZeneca receiving global exclusive rights to Sinopharm's monthly injection weight management product portfolio, including the clinical-ready project SYH2082 and three preclinical projects [2]. - AstraZeneca will pay Sinopharm a $1.2 billion upfront payment, with potential milestone payments of up to $3.5 billion for research and $13.8 billion for sales, along with a double-digit percentage royalty based on annual net sales of the licensed products [2]. Group 2: Market and Product Insights - The core product SYH2082 is a long-acting GLP1R/GIPR agonist, positioned in the rapidly growing metabolic disease treatment market, which has exceeded $50 billion globally [3]. - The market for GLP-1 drugs is expected to continue growing due to rising obesity and diabetes rates, with significant sales projections for competitors like Eli Lilly and Novo Nordisk [3]. - Sinopharm's long-acting technology allows for extending the dosing interval from weekly to monthly, which enhances patient compliance and market penetration, a key reason for AstraZeneca's willingness to invest heavily [4]. Group 3: Industry Implications - This collaboration signifies a historic leap for the Chinese pharmaceutical industry from "catching up" to "running alongside" global peers, transitioning from "licensing in" to "licensing out" [4]. - The partnership emphasizes the need for Chinese companies to possess international vision, top-tier scientific platforms, and strong preclinical research and business negotiation capabilities to succeed in the global market [4]. - Long-term success in Chinese innovation drugs requires a shift from sporadic "blockbuster deals" to systematic, sustainable high-quality innovation, relying on the long-term collaborative development of the entire industry chain [5].